Details of Disease

General Information of Disease (ID: DISZA5CE)

• Disease Name: Chronic idiopathic urticaria
• Synonyms: chronic idiopathic urticaria; idiopathic urticaria, chronic; chronic spontaneous urticaria
• Disease Class: EB00: Spontaneous urticaria
• Definition: Chronic form of idiopathic urticaria.
• Disease Hierarchy:
  DISQUQO3: Idiopathic urticaria
  DISZA5CE: Chronic idiopathic urticaria
• ICD Code:
  ICD-11: ICD-11: EB00.1
  ICD-10: ICD-10: L50.1
  ICD-9: ICD-9: 708
  Expand ICD-11: 'EB00.1
  Expand ICD-10: 'L50.1
  Expand ICD-9: 708
• Disease Identifiers:
  MONDO ID: MONDO_0044212
  MESH ID: D000080223
  UMLS CUI: C0578870
  MedGen ID: 662267
  HPO ID: HP:0410133
  SNOMED CT ID: 302162004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Omalizumab	DMETVFJ	Approved	Monoclonal antibody	[1]

This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GDC-0853	DMBEL3Q	Phase 3	NA	[2]
Ligelizumab	DM103O8	Phase 3	Antibody	[3]
QGE-031	DME2P45	Phase 3	NA	[2]
LOU064	DME8O5K	Phase 2	NA	[2]
GBR 310	DM7KWJG	Phase 1	NA	[2]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 14 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
TPT1	TT3PTB6	Limited	Altered Expression	[4]
LTC4S	TTW7OTG	moderate	Genetic Variation	[5]
ALOX5AP	TTDMBF5	Strong	Genetic Variation	[6]
AOC1	TTM3B5R	Strong	Biomarker	[7]
ARSA	TTYQANR	Strong	Biomarker	[8]
ENPP3	TTD4TKP	Strong	Altered Expression	[9]
FCER2	TTCH6MU	Strong	Altered Expression	[10]
FGL2	TTYBS89	Strong	Biomarker	[11]
HRH1	TTTIBOJ	Strong	Genetic Variation	[12]
IL24	TT1EPXZ	Strong	Biomarker	[13]
KLK5	TTULSEW	Strong	Altered Expression	[14]
KLKB1	TTN0PCX	Strong	Biomarker	[14]
PTGDR	TTNVEIR	Strong	Biomarker	[15]
PTGDR2	TTQDMX5	Strong	Biomarker	[16]

This Disease Is Related to 4 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CD5L	OTPY4WQR	Strong	Altered Expression	[17]
COL17A1	OTID5AH2	Strong	Biomarker	[18]
FCER1A	OTIRUOHF	Strong	Genetic Variation	[19]
TPM4	OTN4YLYR	Strong	Biomarker	[20]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6890).
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT04210843) Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab. U.S. National Institutes of Health.
• [4] Dimerized, Not Monomeric, Translationally Controlled Tumor Protein Induces Basophil Activation and Mast Cell Degranulation in Chronic Urticaria.Immune Netw. 2019 Apr 16;19(3):e20. doi: 10.4110/in.2019.19.e20. eCollection 2019 Jun.
• [5] Familial aggregation of aspirin-induced urticaria and leukotriene C synthase allelic variant. Br J Dermatol. 2006 Feb;154(2):256-60. doi: 10.1111/j.1365-2133.2005.06851.x.
• [6] Polymorphisms of cyclo-oxygenases and 5-lipo-oxygenase-activating protein are associated with chronic spontaneous urticaria and urinary leukotriene E4.Eur J Dermatol. 2011 Jan-Feb;21(1):47-52. doi: 10.1684/ejd.2011.1163.
• [7] Diamine Oxidase Supplementation in Chronic Spontaneous Urticaria: A Randomized, Double-Blind Placebo-Controlled Study.Int Arch Allergy Immunol. 2018;176(3-4):268-271. doi: 10.1159/000488142. Epub 2018 Apr 26.
• [8] Establishing a Safe Administration of ASA in Cardiovascular Patients with Nonsteroidal Anti-Inflammatory Drug Hypersensitivity with Skin and/or Respiratory Involvement.Int Arch Allergy Immunol. 2018;175(4):237-245. doi: 10.1159/000486415. Epub 2018 Jan 26.
• [9] Causal Relationship Between Anti-TPO IgE and Chronic Urticaria by In Vitro and In Vivo Tests.Allergy Asthma Immunol Res. 2019 Jan;11(1):29-42. doi: 10.4168/aair.2019.11.1.29.
• [10] Structural and Physical Basis for Anti-IgE Therapy.Sci Rep. 2015 Jun 26;5:11581. doi: 10.1038/srep11581.
• [11] Genome-wide Analyses of Chromatin State in Human Mast Cells Reveal Molecular Drivers and Mediators of Allergic and Inflammatory Diseases.Immunity. 2019 Nov 19;51(5):949-965.e6. doi: 10.1016/j.immuni.2019.09.021. Epub 2019 Oct 22.
• [12] Human H1 receptor (HRH1) gene polymorphism is associated with the severity of side effects after desloratadine treatment in Chinese patients with chronic spontaneous uticaria.Pharmacogenomics J. 2020 Feb;20(1):87-93. doi: 10.1038/s41397-019-0094-0. Epub 2019 Aug 13.
• [13] Immunological effects and potential mechanisms of action of autologous serum therapy in chronic spontaneous urticaria.J Eur Acad Dermatol Venereol. 2019 Sep;33(9):1747-1754. doi: 10.1111/jdv.15640. Epub 2019 May 15.
• [14] Decreased plasma kallikrein 5 concentrations in patients with chronic spontaneous urticaria.J Biol Regul Homeost Agents. 2017 Apr-Jun;31(2):407-411.
• [15] Looking forward to new targeted treatments for chronic spontaneous urticaria.Clin Transl Allergy. 2017 Jan 10;7:1. doi: 10.1186/s13601-016-0139-2. eCollection 2017.
• [16] Effects of an Oral CRTh2 Antagonist (AZD1981) on Eosinophil Activity and Symptoms in Chronic Spontaneous Urticaria.Int Arch Allergy Immunol. 2019;179(1):21-30. doi: 10.1159/000496162. Epub 2019 Mar 15.
• [17] Validity and responsiveness of the Urticaria Activity and Impact Measure: A new patient-reported tool.Ann Allergy Asthma Immunol. 2018 Jun;120(6):641-647. doi: 10.1016/j.anai.2018.03.012. Epub 2018 Mar 19.
• [18] Immunoglobulin E-Mediated Autoimmunity.Front Immunol. 2018 Apr 9;9:689. doi: 10.3389/fimmu.2018.00689. eCollection 2018.
• [19] Association of FCER1A genetic polymorphisms with risk for chronic spontaneous urticaria and efficacy of nonsedating H1-antihistamines in Chinese patients.Arch Dermatol Res. 2015 Mar;307(2):183-90. doi: 10.1007/s00403-014-1525-z. Epub 2014 Nov 21.
• [20] Identification and validation of differentially expressed proteins in serum of CSU patients with different duration of wheals using an iTRAQ labeling, 2D-LC-MS/MS.Exp Ther Med. 2018 Dec;16(6):4527-4536. doi: 10.3892/etm.2018.6818. Epub 2018 Oct 1.